Infliximab

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
BACKGROUND: Anti-drug antibodies (ADAb) frequently form early in the treatment course of infliximab and other tumour necrosis factor …
Marthe Kirkesaether Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Johanna Elin Gehin, Øystein Sandanger, Inge Christoffer Olsen, Rolf Anton Klaasen, David John Warren, Cato Mørk, Tore K. Kvien, Jørgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm, Silje Watterdal Syversen
Cite DOI
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Importance: Proactive therapeutic drug monitoring (TDM), consisting of individualized treatment based on scheduled assessments of serum …
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, Marthe Kirkesæther Brun, Øystein Sandanger, Kristin Hammersbøen Bjørlykke, Joseph Sexton, Inge Christoffer Olsen, Johanna Elin Gehin, David John Warren, Rolf Anton Klaasen, Geir Noraberg, Trude Jannecke Bruun, Christian Kvikne Dotterud, Maud-Kristine Aga Ljoså, Anne Julsrud Haugen, Rune Johan Njålla, Camilla Zettel, Carl Magnus Ystrøm, Yngvill Hovde Bragnes, Svanaug Skorpe, Turid Thune, Kathrine Aglen Seeberg, Brigitte Michelsen, Ingrid Marianne Blomgren, Eldri Kveine Strand, Pawel Mielnik, Roald Torp, Cato Mørk, Tore K. Kvien, Jørgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm
Cite DOI
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Importance: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum …
Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Øystein Sandanger, Joseph Sexton, Inge Christoffer Olsen, Johanna Elin Gehin, David John Warren, Marthe Kirkesæther Brun, Rolf Anton Klaasen, Lars Normann Karlsen, Geir Noraberg, Camilla Zettel, Maud-Kristine Aga Ljoså, Anne Julsrud Haugen, Rune Johan Njålla, Trude Jannecke Bruun, Kathrine Aglen Seeberg, Brigitte Michelsen, Eldri Kveine Strand, Svanaug Skorpe, Ingrid Marianne Blomgren, Yngvill Hovde Bragnes, Christian Kvikne Dotterud, Turid Thune, Carl Magnus Ystrøm, Roald Torp, Pawel Mielnik, Cato Mørk, Tore K. Kvien, Jørgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm
Cite DOI
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BACKGROUND: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is …
Kristin K. Jørgensen, Guro L. Goll, Joe Sexton, Nils Bolstad, Inge C. Olsen, Øivind Asak, Ingrid P. Berset, Ingrid M. Blomgren, Katrine Dvergsnes, Jon Florholmen, Svein O. Frigstad, Magne Henriksen, Jon Hagfors, Gert Huppertz-Hauss, Espen A. Haavardsholm, Rolf A. Klaasen, Bjørn Moum, Geir Noraberg, Ulf Prestegård, Jan H. Rydning, Liv Sagatun, Kathrine A. Seeberg, Roald Torp, Cecilia Vold, David J. Warren, Carl M. Ystrøm, Knut E. A. Lundin, Tore Kvien, Jørgen Jahnsen
Cite DOI
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
BACKGROUND: Infliximab (INX) and other tumour necrosis factor inhibitors (TNFi) have revolutionised the treatment of several immune …
Silje W. Syversen, Guro L. Goll, Kristin K. Jørgensen, Inge C. Olsen, Øystein Sandanger, Johanna E. Gehin, David J. Warren, Joseph Sexton, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, Nils Bolstad, Espen A. Haavardsholm
Cite DOI
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that …
G. L. Goll, K. K. Jørgensen, J. Sexton, I. C. Olsen, N. Bolstad, E. A. Haavardsholm, K. E. A. Lundin, K. S. Tveit, M. Lorentzen, I. P. Berset, B. T. S. Fevang, S. Kalstad, K. Ryggen, D. J. Warren, R. A. Klaasen, Ø Asak, S. Baigh, I. M. Blomgren, Ø Brenna, T. J. Bruun, K. Dvergsnes, S. O. Frigstad, I. M. Hansen, I. S. H. Hatten, G. Huppertz-Hauss, M. Henriksen, S. S. Hoie, J. Krogh, I. P. Midtgard, P. Mielnik, B. Moum, G. Noraberg, A. Poyan, U. Prestegård, H. U. Rashid, E. K. Strand, K. Skjetne, K. A. Seeberg, R. Torp, C. M. Ystrøm, C. Vold, C. C. Zettel, K. Waksvik, B. Gulbrandsen, J. Hagfors, C. Mørk, J. Jahnsen, T. K. Kvien
Cite DOI
Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply
Kristin K. Jørgensen, Knut E. Lundin, Inge C. Olsen, Tore K. Kvien, Jørgen Jahnsen
Cite DOI
Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register
OBJECTIVES: Tumour necrosis factor-α inhibitor (TNFi) treatment has been shown to reduce the rates of anterior uveitis (AU) in patients …
Elisabeth Lie, Ulf Lindström, Tatiana Zverkova-Sandström, Inge C. Olsen, Helena Forsblad-d'Elia, Johan Askling, Meliha C. Kapetanovic, Lars Erik Kristensen, Lennart T. H. Jacobsson
Cite DOI
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
BACKGROUND: TNF inhibitors have improved treatment of Crohn’s disease, ulcerative colitis, spondyloarthritis, rheumatoid …
Kristin K. Jørgensen, Inge C. Olsen, Guro L. Goll, Merete Lorentzen, Nils Bolstad, Espen A. Haavardsholm, Knut E. A. Lundin, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, NOR-SWITCH study group
Cite DOI